NasdaqCM:VKTXBiotechs
What Viking Therapeutics (VKTX)'s New Maintenance Study for VK2735 Means for Shareholders
Viking Therapeutics recently announced the initiation of a Phase 1 exploratory maintenance dosing study for VK2735, its dual GLP-1/GIP agonist, to evaluate both oral and subcutaneous dosing regimens for obesity treatment in adults.
This progress marks a meaningful advancement within Viking's obesity pipeline, as the study explores strategies for sustaining weight loss beyond initial treatment phases.
We'll examine how this new maintenance dosing study could strengthen Viking's investment...